



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 03/18/2024 14:19 Received: 03/18/2024 14:19

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Brivaracetam, Serum/Plasma, None Detected, mcg/mL, NMRL

Reporting Limit: 0.10 mcg/mL
Synonym(s): Briviact(R)
The recommended steady-state brivaracetam plasma concentration for seizure control is 0.2 to 2.0 mcg/mL.
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.
Digital data review may have taken place remotely by qualified NMS staff utilizing a secure VPN connection for some or all of the reported results. This is in accordance with and follows CLIA regulations.

Testing performed at NMS Labs, Inc.
200 Welsh Road
Horsham, PA 19044-2208
CLIA 39D0197898

Reported Date: 03/18/2024 14:19 BRIVA

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F918000030 Ordered By: KAJAL SITWALA, MD, PhD
WX0000003827 WX00000000002365
Printed D&T: 03/18/24 14:20

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1